Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Development
Brought to you by:
Biotech
Candel burns bright as phase 3 cancer win sends stock up 200%
Candel reported a 14.5% relative improvement in disease-free survival, an endpoint that looked at cancer recurrence or death from any cause.
Nick Paul Taylor
Dec 11, 2024 9:49am
NewAmsterdam shares sign drug improves cardiovascular outcomes
Dec 10, 2024 8:48am
Roivant’s midstage asset fails to show benefit in lung disease
Dec 3, 2024 10:32am
Pyxis' shares fall on lukewarm early ADC results in solid tumors
Nov 21, 2024 2:30pm
NewAmsterdam’s cholesterol ph. 3 hits, but disappoints investors
Nov 20, 2024 10:07am
J&J, Protagonist's oral psoriasis prospect scores in phase 3s
Nov 19, 2024 11:44am